Clinical Trial

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-24.
Trial Details
NCT Number NCT07499700
Lead Sponsor Bio-Thera Solutions
Conditions Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
Enrollment 192 participants
Start Date 2025-10-26
Primary Completion 2030-10-26 (estimated)
Study Completion 2030-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-04-03